

China-based startup Rona Therapeutics raises \$35 M to advance metabolic siRNA pipeline

19 July 2024 | News

To progress leading metabolic siRNA pipeline programmes into global development



China-based startup Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, has announced the completion of \$35 million Series A+ financing.

This round was led by LongRiver Investments, with participation from investors including Zhaode Investment, BioTrack Capital, Zhongqi Capital and Lilly Asia Ventures.

LongRiver Investments will join the board of Rona in connection with the Series A+ financing, commented, "Rona Therapeutics has successfully brought two best-in-class siRNA metabolic programs into global development and demonstrated differentiated clinical data and platform value. We are impressed by the progress Rona has made in developing innovative siRNA pipeline and expanding into extrahepatic delivery in CNS and beyond. We look forward to partnering with Rona team to unlock potential of RNA medicine as transformative therapies to patients globally."

Rona is advancing a pipeline of best and first-in-class siRNA programs generated from next generation siRNA platform. The company's first program RN0191, a best-in-class PCSK9 siRNA program, has completed Australia and China Ph1 clinical studies and ready for Ph2 clinical development for hypercholesterolemia.

RN0361 is the company's second programme to enter clinic in 2024Q2 for hypertriglyceridemia. The company is also advancing innovative pipeline at IND enabling stage for kidney disease, obesity and cardiometabolic diseases.